Docket Number:10A-1001025
Inventor:Han-Chung Wu, Mei-Yin Liao, Cheng-Wei Lin
IP Status:US 9187558, TW I 485161, China ZL201380012187.0, EP pending, JP pending
Abstract:
For development of therapeutic antibodies, we newly generated five EpCAM mAbs including EpAb2-6, which could induce cancer cell apoptosis and inhibit tumor growth. EpAb2-6 was successfully converted to a humanized version that retained cancer killing activity for induction of cancer cell apoptosis. EpCAM mAbs can be used for cancer diagnosis and prognosis, and cancer-targeted therapy and imaging.
Fields of Application:
- Development of therapeutic antibody for treatment of EpCAM over-expressed solid tumor.
- Development of diagnostic or reagents for cancer
- Development of targeting drug delivery systems for cancer therapy.
- Development of targeting imaging for cancer.
Advantages when compared to the existing technologies:
We have newly generated 12 monoclonal antibodies (mAbs) which specifically binds to HNSCC but not to normal cells. The present invention relates to anti-EpCAM monoclonal antibodies for inhibition of tumor growth. The mAbs specifically binds to various cancer cells but not normal cells. These mAbs have higher affinity and cancer killing activity than published papers, will be useful to develop therapeutic antibodies, diagnostic reagents, targeting drug delivery systems and imaging.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
